Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.

Abstract: Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.

Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.

Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.

Abstract: The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.

Abstract: The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.

Abstract: The use of a therapeutic capable of inhibiting complement, e.g., an anti-C5 antibody, to treat antibody mediated neuropathies is disclosed.

Abstract: Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.

Abstract: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.

Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.

Abstract: Murine and humanized anti-human VEGF antibodies and uses are disclosed. The anti-human VEGF antibodies of the invention have higher binding affinity for human VEGF-A, are stronger inhibitors of the VEGF-A induced proliferation of endothelial cells in culture as compared with anti-human VEGF antibodies in the art. Moreover, these antibodies cross react with human VEGF-B. The antibodies of the invention inhibit tumor growth in vivo in greater extent than Bevacizumab when administered at the same dosage.

Abstract: An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human TNF. Such binding disrupts assembly of the monomer into bioactive trimeric human sTNF. A pharmaceutical composition contains one or more antibodies or ligands: (a) an antibody or ligand that specifically binds the TNF monomer-specific epitope having the sequence PSDKPVAH or PSDKPVAHV, amino acids 8-15 or 8-16 of SEQ ID NO: 1; and (b) an antibody or ligand that specifically binds the TNF monomer-specific epitope having the sequence EPIYLGGVF, amino acids 116 to 124 of SEQ ID NO: 1. A combination of antibodies or ligands that bind or are reactive with (a) and/or (b) are useful in methods for treating a subject having a disease (e.g., rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis, atherosclerosis, metabolic syndrome, Alzheimer's Disease, HIV, Type II diabetes) mediated by human TNF.

Abstract: Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.

Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.

Abstract: A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions.

Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.

Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.

Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.

Abstract: The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to the 414H5 and 515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.

Abstract: The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.

Abstract: Soluble adenylyl cyclase (sAC) is implicated in proliferation of keratinocytes. Inhibitors of sAC are useful for the treatment and/or prevention of psoriasis and other hyperproliferative skin disorders. Assays to identify such compounds are also described.

Abstract: A biorefining method of processing a lignocellulosic biomass to separate lignin and hemicellulose from cellulose includes the steps of (a) reacting the biomass in an aqueous slurry having a pH less than 7, comprising a transition metal catalyst, hydrogen peroxide; and (b) separating a solid cellulose fraction from dissolved lignin and hemicellulose fractions. The method may also be used to treat cellulose and produce microcrystalline or nanocrystalline cellulose. The transition metal catalyst may be a nanoparticulate catalyst including multivalent iron, iron oxides and iron hydroxides. The nanoparticulate catalyst may be formed by oxidizing a highly reduced solution of iron, such as groundwater that has not been exposed to oxygen.

Abstract: Methods for removing endotoxin from naturally occurring materials, such as polysaccharides (e.g., agarose and/or carrageenan) are described herein. Polysaccharides that are substantially free of endotoxins and uses thereof are also described. The polysaccharide materials can be isolated from microorganisms, multicellular organisms, such as, algae, plants, seaweed, etc. The method involves the use of acidic and basic solutions to hydrolyze the lipid-polysaccharide bond in endotoxins. Cleaving the fatty acid from the polysaccharide reduces the water-solubility of the fatty acid and enables its removal with an organic solvent such as ethanol. The polysaccharide component can also undergo acidic or basic hydrolysis due to the weak glycosidic bond between the sugar rings.

Abstract: Catalyst compounds for water-based two-component coating compositions include: I) an organo-metal catalyst for a curing reaction between isocyanate groups and functional groups reactive towards isocyanate groups and II) an oligomeric or polymeric binder compound having a glass transition temperature Tg of ?20° C., measured by DSC (differential scanning calorimetry) at a heating rate of 10 K/min. The glass transition temperature Tg of binder compound II) is above the temperature at which a water-based two-component coating composition comprising the catalyst compound is applied, preferably is at least 10° C., more preferred at least 20° C., above the temperature at which the two-component coating composition is applied.

Abstract: The invention provides a polymerization process comprising polymerizing a reaction mixture comprising one or more monomer types, at least one catalyst, and at least one solvent, to form a polymer dispersion, and wherein the at least one catalyst is soluble in the at least one solvent, and wherein the polymer forms a dispersed phase in the solvent, and wherein the at least one solvent is a hydrocarbon. The invention provides a composition comprising an ethylene-based polymer comprising at least the following properties: a) a weight average molecular weight (Mw(abs)) greater than, or equal to, 60,000 g/mole; and b) a molecular weight distribution (Mw(abs)/Mn(abs)) greater than, or equal to, 2.3.

Abstract: This invention relates to relates to a polyolefin composition comprising one or more of the following formulae: wherein the PO is the residual portion of a vinyl terminated macromonomer (VTM) having had a terminal unsaturated carbon of an allylic chain and a vinyl carbon adjacent to the terminal unsaturated carbon.

Abstract: Functionalization of polymers, including polyolefins, via decomposition of organic peroxides through the use of solid-state shear pulverization.

Abstract: Fluoropolymers containing one or more azide group wherein the azide group is not a sulfonyl-azide group and processes of preparing them.

Abstract: The present invention relates to ionomers comprising a reaction product of the reaction between a halogenated isoolefin copolymer and at least one phosphorus based nucleophile comprising at least one pendant vinyl group. The present invention also relates to a method of preparing and curing these ionomers.

Abstract: To provide a photosensitive polymer, a phase difference film using the photosensitive polymer, and an optical film using the phase difference film. A solution is a photosensitive polymer having a constitutional unit represented by formula (1): wherein, in formula (1), for example, R1 is hydrogen or methyl; a is 2 or 3; p is an integer from 1 to 12; X1 is —O—, —COO— or —OCO—; b is an integer from 0 to 3; A1 is a divalent group selected from 1,4-phenylene or naphthalene-2,6-diyl, and in the divalent group, at least one of hydrogen may be replaced by fluorine or chlorine; Z1 is a single bond, —COO—, —CH?CH—COO—, —CH2CH2—COO—, —CH2O— or —CONH—; W1 and W2 are hydrogen, fluorine or 1-5C alkyl or alkoxy; Y1 is —O—; and R2 is 1-20C alkyl, and at least one of —CH2— in the alkyl may be replaced by —O—.

Abstract: The invention provides an ethylene-based polymer formed from at least the following: ethylene and a monomeric chain transfer agent (monomeric CTA) selected from Structure 1: wherein L is selected from a saturated hydrocarbon, a substituted saturated hydrocarbon, an unsaturated hydrocarbon, or a substituted unsaturated hydrocarbon; R1 is selected from hydrogen, a saturated hydrocarbon, a substituted saturated hydrocarbon, an unsaturated hydrocarbon, or a substituted unsaturated hydrocarbon; R2 is selected from hydrogen, a saturated hydrocarbon or a substituted saturated hydrocarbon; R3 is selected from hydrogen, a saturated hydrocarbon or a substituted saturated hydrocarbon; and R4 is selected from a saturated hydrocarbon, a substituted saturated hydrocarbon, an unsaturated hydrocarbon, or a substituted unsaturated hydrocarbon.

Abstract: Ethylene copolymers having a relatively high melt flow ratio and a multimodal profile in a temperature rising elution fractionation (TREF) plot are disclosed. The copolymers can be made into film having good dart impact values and good stiffness properties under decreased extruder pressures.

Abstract: A process for producing a fluorinated olefin/vinyl alcohol copolymer, which comprises emulsion polymerizing a fluorinated olefin and a vinyl ether in the presence of an aqueous medium and an emulsifier and converting the repeating units based on the vinyl ether to the vinyl alcohol.

Abstract: Provided is a copolymer having excellent calcium ion trapping ability, calcium carbonate dispersing capacity, and gel resistance. A (meth)acrylic acid-based copolymer contains, as essential structural units, a structural unit (a) derived from a monomer represented by the following formula (1) in an amount of 2% by mole or more and 9% by mole or less, and a structural unit (b) derived from a (meth)acrylic acid (salt) in an amount of 91% by mole or more and 98% by mole or less, relative to 100% by mole of structural units derived from all monomers, wherein the copolymer contains a sulfonic acid (salt) group at least one end of the main chain and has a weight average molecular weight of 7000 to 100000, wherein R2 represents a hydrogen atom or a methyl group; and X and Y each independently represent a hydroxyl group or a sulfonic acid (salt) group (at least one of X and Y represents a sulfonic acid (salt) group).

Abstract: A method for producing a resin composition, comprising the step of: subjecting a radical copolymerization of a first radical polymerizable monomer which is free from any crystalline molecular chain and a second radical polymerizable monomer having a crystalline molecular chain, in the presence of a radical polymerization initiator, wherein the second radical polymerizable monomer is the following compound, (wherein R1 denotes a hydrogen atom or a methyl group, and R2 denotes an alkyl group having at least 17 carbon atoms) the first radical polymerizable monomer has a particular reactivity ratio.

Abstract: Methods for producing a silyl-functionalized polyolefin with silyl monomer incorporation are provided. The method includes reacting a silicon-containing olefin with an ?-olefin, in the presence of a catalytic amount of a group IV catalyst for a time sufficient to produce a silyl-functionalized polyolefin.

Abstract: The invention provides a fluoro-containing ether monomer for fabricating contact lenses represented by following formula (I): In formula (I), R10 is fluoroalkyl group (CxFyHz, wherein x is an integer of 2-20, y is an integer of 5-30, and y+z=2x?1), R11 is oxygen, nitrogen or sulfur; R12 is C1-C3 alkylene; n is an integer of 3-40.

Abstract: A photocurable elastomer composition comprising: (A) a liquid polymer having a number average molecular weight of 5,000 or more, and mainly containing —[CH2C(CH3)2]— units; (B) a (meth)acrylate monomer; and (C) a photo polymerization initiator, the mass ratio ((A):(B)) between the component (A) and the component (B) being 10:90 to 39:61.

Abstract: Provided are novel polymer brushes that may be used in underlying buffer or imaging layers for block copolymer lithography. The novel polymer brushes include X-A-b-B and X-A-b-C block copolymer brushes, with X an anchoring group, the A block a lithographically sensitive polymer, and the C block a random copolymer. According to various embodiments, polymer block brushes for neutral and preferential layers are provided; the neutral layers non-preferential to the overlying block copolymer and the preferential layers preferential to a block of the overlying block copolymer. Also provided are novel methods of patterning polymer block brush layers as well as polymer block brush buffer and imaging layers that are directly patternable by e-beam, deep UV, extreme UV, X-ray or other lithographic methods.

Abstract: Amino-formaldehyde resins, articles of manufacture from the amino-formaldehyde resins, and processes for making the resins and articles are provided herein. In one embodiment, the amino-formaldehyde resins may be prepared using a reaction mixture including formaldehyde, a monohydroxy cyclic compound, and at least one amino compound selected from the group consisting of urea, melamine, and mixtures thereof. In another embodiment, the amino-formaldehyde resins are produced by reacting formaldehyde, a monohydroxy cyclic compound, and at least one amino compound selected from the group consisting of urea, melamine, and mixtures thereof, and the monohydroxy cyclic compound may be added as a front addition, an intermediate addition, a back addition, or a combination thereof, to the reaction mixture of formaldehyde and the at least one amino compound.

Abstract: The present invention provides sizing compositions and methods of using the same for glass fibers used in reinforced polymeric composites produced by reactive processing techniques.

Abstract: There is provided a polyoxyalkylene polyol or monool (S) represented by formula (2). In the formula (2), R2 represents an m-valent group in which m active hydrogens are removed from the active hydrogen-containing compound (H); Z is an alkylene group or a cycloalkylene group, and these groups are unsubstituted or substituted with a halogen atom or an aryl group. A hydroxyl value x, total degree of unsaturation y and the content of ethylene oxide z satisfy mathematical expression (3). In mathematical expression (3), x represents 5 to 280 mgKOH/g, y represents total degree of unsaturation represented by a unit meq/g, and z is from 0 to 50. R2—[—(ZO)p-(AO)q-(CH2CH2O)r-H]??(2) y?18.

Abstract: There is provided a method of synthesizing a segmented copolymer that includes mixing one or more ?,? (alpha, omega) amine or ?,? (alpha, omega) hydroxyl terminated polysiloxane first soft segments having an average molecular weight of between about 2500 grams per mole to about 10,000 grams per mole, and one or more diisocyanate species, together to form a first reaction product; mixing the first reaction product and one or more low molecular weight diol or diamine chain extenders each having an average molecular weight of less than 400 grams per mole, together in a solvent to form a segmented copolymer; and, removing the solvent.

Abstract: The invention provides a novel platform for minimal- or non-flammable polymers, which is based purely on hydrocarbon systems and does not need additives of any kind A key feature is that the hydrocarbons disclosed herein are characterized by degradation mechanisms that produce few flammable volatiles. For example, 2,4,4?,6-tetrahydroxydeoxybenzoin is employed as a multifunctional cross-linker in conjunction with bis-epoxydeoxybenzoin, affording new resins that combine excellent physical and mechanical properties with low flammability.

Abstract: Bisanhydrohexitol derivatives having terminal mercapto groups are provided. Additionally, curable compositions that include these mercapto-containing bisanhydrohexitol derivatives, cured compositions prepared from the curable compositions, and articles containing the cured compositions are provided. More specifically, the curable compositions are epoxy-based formulations and the mercapto-containing bisanhydrohexitol derivatives function as curing agents for epoxy resins.

Abstract: Methods to form a polymer by ring-opening polymerization include reacting, a mixture comprising a monomer, an accelerator, an initiator, and a catalyst comprising a 1,1,1,3,3,3-hexafluoropropan-2-ol-2-yl group to form the polymer. Also disclosed are polymers including a residual amount of the catalyst in an amount greater than 0 weight percent.

Abstract: The invention generally relates to functional polymers and hydrogels. More particularly, the invention provides versatile monomers and polymers with well-defined functionalities, e.g., polycarbonates and poly(ester-carbonates), compositions thereof, and methods for making and using the same. The invention also provides cytocompatible poly(ethylene glycol)-co-polycarobonate hydrogels (e.g., crosslinked by copper-free, strain-promoted “click” chemistry).

Abstract: In one aspect, the present disclosure encompasses polymerization systems for the copolymerization of CO2 and epoxides comprising 1) a catalyst including a metal coordination compound having a permanent ligand set and at least one ligand that is a polymerization initiator, and 2) a chain transfer agent having one or more sites capable of initiating copolymerization of epoxides and CO2, wherein the chain transfer agent contains one or more masked hydroxyl groups. In a second aspect, the present disclosure encompasses methods for the synthesis of polycarbonate polyols using the inventive polymerization systems. In a third aspect, the present disclosure encompasses polycarbonate polyol compositions characterized in that the polymer chains have a high percentage of —OH end groups, a high percentage of carbonate linkages, and substantially all polycarbonate chains having hydroxyl end groups have no embedded chain transfer agent.

Abstract: Disclosed is a substrate structure for manufacturing a flexible electronic device, including a supporting layer, a release layer covering the supporting layer with a first area, wherein the release layer is an aromatic polyimide, and a flexible layer covering the supporting layer and the release layer with a second area. The second area is greater than the first area. The adhesion force between the flexible layer and the supporting layer is stronger than the adhesion force between the release layer and the supporting layer.

Abstract: A poly(imide-amide) copolymer, which is a product of a reaction between a diamine and a dianhydride, wherein the diamine comprises a diamine represented by Chemical Formula 1 and the dianhydride comprises a dianhydride represented by Chemical Formula 5: wherein, the variables in Chemical Formulae 1 and 5 are described in the specification.